Inhibikase Therapeutics, Inc. announced the appointment of Ms. Gisele Dion to its Board of Directors, effective September 1, 2022. Ms. Dion will serve as chair of the Audit Committee and a member of the Compensation Committee following the retirement of Ms. Elizabeth O'Farrell from the Company's Board of Directors, effective immediately. Ms. Dion is currently a member of the Board of Directors at Cytek Biosciences and most recently served as an Audit Advisor Group Member for the Pharmaceutical Research and Manufacturers of America (PhRMA).

Previously, she served as the Senior Vice-President and Chief Accounting Officer at Takeda Pharmaceuticals where she advised the CFO and protected assets, including $30B+ in revenue. While at Takeda, Ms. Dion successfully led the company through SEC registration and guided change management initiatives. Prior to Takeda, she was the Chief Accounting Officer and Corporate Controller at Shire Pharmaceuticals, where she spearheaded M&A integrations, SEC adherence and GAAP compliance from 2016 to 2019, when it was acquired by Takeda.

Earlier, Ms. Dion was Corporate Controller at Biogen. Ms. Dion holds a B.S. in Accounting and Management Information Systems from Fairfield University.